Kunzendorf et al., 1998 - Google Patents
The Th1-Th2 paradigm in 1998: law of nature or rule with exceptions.Kunzendorf et al., 1998
View PDF- Document ID
- 9553835198082327060
- Author
- Kunzendorf U
- Tran T
- Bulfone-Paus S
- Publication year
- Publication venue
- Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association-European Renal Association
External Links
Snippet
Introduction tin in vitro, particularly when stimulated with growth Osteopontin is a multifunctional protein which is pro-factors, cytokines or 1, 25 (OH) 2-vitamin D [6–8]. In duced not only in bone and cartilage as its name the normal kidney osteopontin is …
- 230000000268 renotropic 0 abstract description 82
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Schrier | Renal and electrolyte disorders | |
| Van Assche et al. | A pilot study on the use of the humanized anti-interleukin-2 receptor antibody daclizumab in active ulcerative colitis | |
| Hill et al. | Differential roles of IL-1 and TNF-α on graft-versus-host disease and graft versus leukemia | |
| US5919444A (en) | Method for decreasing severity of acute and chronic pancreatitis | |
| Murphy et al. | New strategies for preventing graft-versus-host disease | |
| Kunzendorf et al. | The Th1-Th2 paradigm in 1998: law of nature or rule with exceptions. | |
| WO1993011793A1 (en) | Use of the combination of anti-tumor necrosis factor plus interleukin-6 to treat septic shock | |
| Nakamura et al. | Efficacy of etanercept in patients with AA amyloidosis secondary to rheumatoid arthritis | |
| Takeuchi et al. | Phase II dose–response study of abatacept in Japanese patients with active rheumatoid arthritis with an inadequate response to methotrexate | |
| Su et al. | Autologous peripheral blood stem cell transplantation for severe multiple sclerosis | |
| JPH0776179B2 (en) | Composition for treating diseases including immunological factors | |
| US20070274984A1 (en) | Methods for treating autoimmune diseases using a taci-ig fusion molecule | |
| Noel et al. | Renal failure and bone marrow transplantation. | |
| Fujii et al. | The rapid efficacy of abatacept in a patient with rheumatoid vasculitis | |
| Giralt et al. | Phase I trial of cyclosporine-induced autologous graft-versus-host disease in patients with multiple myeloma undergoing high-dose chemotherapy with autologous stem-cell rescue. | |
| Sagami et al. | Successful use of adalimumab for treating pyoderma gangrenosum with ulcerative colitis under corticosteroid-tapering conditions | |
| US20140170125A1 (en) | Use of cardiotrophin-1 for the treatment of kidney diseases | |
| JPH05502434A (en) | Pharmaceutical compositions and their uses | |
| Huang et al. | A novel apoptosis‐inducing anti‐PSGL‐1 antibody for T cell‐mediated diseases | |
| JP2021521121A (en) | Methods for treating autoimmune diseases | |
| Michie et al. | Sepsis and tumor necrosis factor--bedfellows that cannot be ignored | |
| JP2005516907A (en) | Use of primate IFN-gamma binding molecules | |
| Budde et al. | Dendritic polyglycerol sulfate attenuates murine graft-versus-host disease | |
| Werring et al. | Systemic conditions and neurology | |
| US20220354872A1 (en) | Pharmaceutical composition and use thereof for relieving progression of chronic kidney disease or preventing thereof |